Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioNTech SE

Pfizer

The European Medicines Agency said Tuesday it has received conditional marketing approval applications from Pfizer Inc. (NYSE: PFE)-BioNTech SE – ADR (NASDAQ: BNTX) and Moderna Inc (NASDAQ: MRNA), the two frontrunners in the development of a coronavirus vaccine.  The decision isn't likely to come early, thereby pushing out the vaccine launch timeline.

European Drug Regulator Gives 6-Week Time Frame For Opinions On Pfizer-BioNTech, Moderna COVID-19 Vaccines

Momentum from the biotech's announcement on Monday of an EUA filing for mRNA-1273 is carrying over to today.

Why Moderna Stock Is Moving Higher Today

Moderna's (MRNA) coronavirus vaccine achieves efficacy rate of 94.1% in primary efficacy analysis. The company files for Emergency Use Authorization to the FDA.

Moderna (MRNA) Seeks Nod for Emergency Use of COVID-19 Vaccine

Moderna and Pfizer applied to the EU's vaccine regulator this week.

Europe May Not Get Covid-19 Vaccine Before 2021, Earliest Approval Process Scheduled For December 29

AstraZeneca

Gilead Sciences

Eli Lilly

Shares of Moderna, Inc. (MRNA), Pfizer, Inc. (PFE) and AstraZeneca plc (AZN) are poised for substantial gains on encouraging final-stage trial results.

COVID-19 Vaccine Race Heats Up: Drugmarkers on Final Lap

Fastly

Tilray Brands

These stocks could make investors rich next month.

3 Top Breakout Stocks to Watch in December

The European Medicines Agency said on Tuesday it has received an application for marketing authorization for Moderna Inc's COVID-19 vaccine candidate.

Moderna files for European authorization of COVID-19 vaccine candidate

The outside experts will give their opinions in a couple of weeks.

Moderna's Coronavirus Vaccine to Be Reviewed by FDA Advisory Committee on Dec. 17

Apple

General Motors

Nikola

SPDR S&P 500 ETF Trust

Apple, General Motors, Nikola, Moderna and the S&P 500 ETF were our top stock trades for Tuesday. Now, let's look at the charts.

5 Top Stock Trades for Tuesday: AAPL, NKLA, GM, MRNA, SPY

Final-phase testing confirmed Moderna's coronavirus vaccine is 94.1% effective at blocking Covid-19, the biotech company said Monday. Now, Moderna plans to ask for emergency authorization.

Moderna Hits A Record High As It Seeks FDA OK For Coronavirus Vaccine

AGCO

Ardagh Group

Brandywine Realty

Brookfield Property REIT

Salesforce

GrafTech International Ltd.

Enphase Energy

NortonLifeLock

NRG Energy

Peloton

Rockwell Automation

Tesla

Zoom Video

These are the stocks with the best value, fastest growth, and most momentum for December.

Top Stocks for December 2020

Moderna will waste no time vaccinating Americans after a potential FDA greenlight.  After the company announced it would file for emergency-use authorization with the US Food and Drug Administration on Monday, the biotech company's CEO, Stéphane Bancel, said in an interview that Americans will start getting vaccinated "within 24 hours after the FDA gives an approval." 

Moderna CEO said he hopes to be vaccinating Americans 'within 24 hours' of an FDA green light (MRNA)

The stock market rally took a pause Monday afternoon.

Nikola Puts the Brakes on the Nasdaq Rally -- But Moderna's Soaring Again

The stock price of Moderna Inc (NASDAQ: MRNA) is trading at more than 15% throughout the day today. This is why.

MRNA Stock Price Increases Over 15%: Why It Happened

Positive Development on COVID-19 Vaccine Front

New data confirms that Moderna Inc's (NASDAQ:MRNA) COVID-19 vaccine is more than 94% effective, and the company is planning to request emergency use authorization from the Food and Drug Administration (FDA) today.

Another Record High for MRNA Following Vaccine Update

Moderna (MRNA) amends its present contract with the United Kingdom government to supply two million additional doses of its coronavirus vaccine candidate, mRNA-1273, upon approval.

Moderna (MRNA) Amends Coronavirus Vaccine Supply Deal in U.K.

Overall efficacy has reached 94.1%, with treatment of severe cases of Covid proving 100% effective.

Moderna (MRNA) Takes to Lead in Covid Sweepstakes

CVS Health

Johnson & Johnson

Teladoc

These healthcare stocks can deliver steady growth in the coming decade as demographics suggest tailwinds for the industry. The post 4 Healthcare Stocks That Will Take Care of You appeared first on InvestorPlace.

4 Healthcare Stocks That Will Take Care of You

The company released successful clinical trial results that will support an upcoming request for Emergency Use Authorization of mRNA-1273.

Moderna's Coronavirus Vaccine Candidate 100% Effective at Preventing Severe COVID-19

Moderna Inc. (NASDAQ: MRNA) shares continued to run higher on Monday after the company announced an update for the primary efficacy analysis for its late-stage coronavirus vaccine trial.

Moderna's COVID-19 Vaccine Is on the Way: Here's What You Need to Know

Beyond Meat

Novavax

Walmart

Costco

Buy low, sell high. Here are some stocks that are very high, on which you can take profits now.

7 Stocks to Sell for Christmas Giving

Moderna Inc (NASDAQ: MRNA) shares, which closed in record territory Friday, are adding to their gains following the release of primary analysis of the Phase 3 study that evaluated its coronavirus vaccine candidate, RNA-m1273, and a disclosure from the company regarding the timeline for filing for emergency use authorization. Primary Analysis Pitches Efficacy at 94.1% The Cambridge, Massachusetts-based company said primary efficacy analysis of data from the study, dubbed COVE, conducted on 196 cases showed vaccine efficacy at 94.1%.

Moderna's Stock Hits New Highs After COVID-19 Vaccine Analysis Confirms 94% Efficacy

But even if the EUA is granted, it will be a while before the average American can get the vaccine. Moderna today will officially file for emergency use authorization from the U.S. Food and Drug Administration for its COVID-19 vaccine.

Moderna files for emergency use authorization from the FDA for its COVID-19 vaccine

Moderna Inc will apply for U.S. and European emergency authorization for its COVID-19 vaccine on Monday after full results from a late-stage study showed it was 94.1% effective with no serious safety concerns, the company said.

News for Moderna Stock (MRNA)